An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Trial Profile

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Levoketoconazole (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SONICS
  • Sponsors Strongbridge Biopharma
  • Most Recent Events

    • 30 Nov 2017 This trial has been completed in Sweden (End date: 2017-07-12)
    • 26 Oct 2017 This trial has been completed in Czech Republic
    • 08 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top